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TargeTed LiTeraTure review Of MediCaTiOn evenT MOniTOring 
SySTeMS TO evaLuaTe adherenCe in ObServaTiOnaL reaL-wOrLd 
STudieS
Hanson K.A., Payne K.A.
United BioSource Corporation, Dorval, QC, Canada
Objectives: To identify and review methods employed to evaluate medication 
adherence in studies of oral antineoplastic agents, with particular interest in the 
opportunities and challenges associated with medication event monitoring systems 
(MEMS) implemented in observational studies. MethOds: A targeted literature 
review was conducted to identify studies that have measured adherence with anti-
neoplastic agents. Our review included studies that were published between January 
1990 and May 2014. Key data abstracted from each study included patient charac-
teristics, study design and duration, cancer type, treatment, and adherence meth-
odology and results. Based on preliminary results, a second targeted review was 
conducted to evaluate the literature on the risk of the Hawthorne effect in obser-
vational studies utilizing MEMS in any therapeutic area. Results: We identified 69 
studies that evaluated adherence to oral chemotherapy; 6 studies were interven-
tional and excluded from further review. Of the remaining 63 studies, 28 (44%) were 
prospective, 25 (40%) were retrospective, and 10 (16%) were cross-sectional. A total 
of 15 studies used MEMS to evaluate medication adherence. Among observational 
studies that utilized MEMS and evaluated the Hawthorne effect (n= 3), mixed results 
were observed. In two studies, patients reported their behavior was affected by their 
awareness of being evaluated. This was demonstrated by a significant decrease in 
adherence between months 1-3 in one study but not measured in the second. The 
third study showed no change in adherence scores over time and concluded there 
was no Hawthorne effect. Potential ways to minimize the Hawthorne effect include: 
study duration > 3 months, blinding patients and physicians to results of MEMS 
downloads, and use of a patient-completed ‘debriefing form’ to assess behavior 
modifications. cOnclusiOns: MEMS have been utilized in observational studies 
evaluating oral antineoplastic agents. The Hawthorne effect may be present with 
MEMS caps, but can be minimized and is not prohibitive to study conduct.
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a SySTeMaTiC review Of heaLTh STaTe uTiLiTy vaLueS fOr advanCed 
Ovarian CanCer
Al-Dakkak I.1, Borrill J.2, Murphy E.1, Posnett J.1, Zhang Y.1
1PAREXEL International, London, UK, 2AstraZeneca, Macclesfield, UK
Objectives: Identifying appropriate utility values to inform cost-effectiveness 
analysis is a common problem. The aim of this study was to review health-state 
utility values (HSUVs) for patients with advanced ovarian cancer and make recom-
mendations about their use in the economic evaluation of a targeted maintenance 
therapy for platinum-sensitive recurrent (PSR) ovarian cancer. MethOds: A sys-
tematic search of Embase®, MEDLINE®, and MEDLINE®in Process was conducted 
in June 2013 for studies reporting direct (standard gamble (SG) or time trade off 
(TTO)) or indirect (EQ-5D, SF-6D, or HUI-3) utility values for patients with advanced 
ovarian cancer. HTA agency websites were also searched. Study design, country, 
HSUV elicitation method, health state (HS) description, and who valued the HS were 
extracted. Mean (SD) utility scores, or medians (ranges), if means were unavailable, 
were recorded for each HS. Results: A total of 10 publications were found, rep-
resenting five primary sources of utility values. Two were derived from trial-based 
patient-reported EQ-5D profiles; one derived profiles from patients with ovarian 
cancer and utility values from a sample of the general population using a SG; two 
derived HSUVs from a sample of women without cancer using a TTO. These studies 
reported utilities for 18 different health states. Where comparisons were possible, 
utility values differed widely: clinical remission 0.83-0.977; progression-free after 
recurrence 0.50-0.715; progressive disease 0.40-0.725. None of the studies reported 
values for patients receiving maintenance therapy. cOnclusiOns: There is limited 
health-state utility data for advanced ovarian cancer and wide variations in sam-
ple size, methods of elicitation, populations used to provide utility values, and in 
health state descriptions. Further research is required to provide robust estimates 
to populate an economic model for a targeted maintenance therapy for PSR ovarian 
cancer. Given the limitations of the current evidence base additional methods, such 
as mapping algorithms should be considered.
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heaLTh-STaTe uTiLiTy vaLueS in breaST and PrOSTaTe CanCer 
MeaSured uSing The eQ-5d: a SySTeMaTiC review Of The LiTeraTure
Hughes R., Mitchell C.R., Bishop R.S., Fotheringham I
Oxford PharmaGenesis Ltd, Tubney, Oxford, UK
Objectives: In cost–effectiveness analyses (CEA), a paucity of health-related qual-
ity of life (HRQoL) data often necessitates use of utility values from populations 
which may be ill-matched with the disease modelled. Use of the most pertinent data 
increases model precision and the accuracy of CEA. This systematic literature review 
aimed to identify utility values derived from the EQ-5D in patients with breast 
cancer (BC) or prostate cancer (PC). MethOds: A systematic search was conducted 
using Medline, Embase and Cochrane databases. Eligible studies for inclusion com-
prised those reporting EQ-5D utility values in patients with BC or PC at any stage, 
undergoing or not receiving treatment. Results: 31 studies reported relevant data 
(BC, 17; PC, 14). Utility values for metastatic BC (6 studies) ranged from 0.55–0.75 
and were lower for patients receiving palliative chemotherapy (CT) or terminal care 
(0.51–60), while for stage 0–III disease (9 studies), values ranged from 0.74–0.88. In 
early-stage BC there was little change during follow-up; for stage II/III BC, rapid 
and sustained recovery was observed following high-dose (HD) CT and was main-
tained long-term post-HDCT and following adjuvant CT. Values for metastatic PC (9 
studies) ranged from 0.63–0.85 and were lower for patients with bone metastases, 
worse performance status or undergoing palliative care. For localised PC (2 studies), 
Objectives: Skeletal-related events (SREs) defined as pathologic fracture, radiation 
to bone, surgery to bone and spinal cord compression, are common consequences 
of bone metastasis. Prior studies have shown that SREs increase the utilization of 
health care resources, including hospitalizations. We estimated the decrease in hos-
pitalizations when a novel superior therapy is used (denosumab), in substitution 
of zoledronic acid (zol), to treat patients with bone metastases secondary to breast 
cancer in Germany. MethOds: An analysis was run for predicting the number of SREs 
avoided and the reduction in number of hospitalizations attributable to treatment 
with denosumab. The number of breast cancer patients was collected from a German 
registry using the International Classification of Disease codes. Epidemiological data 
were then utilized to derive the number of hospitalizations due to bone metasta-
ses. The number of patients treated for SREs prevention was obtained from market 
research and applied to either treatment. The total number of SREs observed was 
based in the SREs rates seen in a phase 3 clinical trial. German data from a multina-
tional retrospective chart review was used to quantify the inpatient hospitalization 
rates and length of stay associated with each type of SRE. Results: Approximately 
9,500 patients per year with breast cancer and bone metastases were estimated to 
be treated with denosumab or zol in Germany. The resulting 2,100 SREs prevented 
per year led to a reduction of approximately 700 hospitalizations per year. The total 
number of days per inpatient stay avoided by using denosumab instead of zol was 
approximately 5,000 per year. cOnclusiOns: The superior efficacy of denosumab 
compared to zol reduces the disease burden by decreasing the number of SREs and 
consequently the number of hospitalizations and inpatient days.
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CLiniCaL iMPLeMenTaTiOn Of genOMiC SeQuenCing in PediaTriC 
OnCOLOgy: idenTifiCaTiOn and vaLuaTiOn Of reSOurCeS and COSTS 
aSSOCiaTed wiTh nexT-generaTiOn SeQuenCing
Oberg J.A., Sireci A.N., Mansukhani M.M., Nagy P.L., Glade Bender J.L, Kung A.L.
Columbia University, New York, NY, USA
Objectives: Beyond understanding the pure cost of genomic sequencing, the 
real costs associated with implementing next-generation sequencing (NGS) into 
clinical practice are currently unknown. To elucidate the real costs and to pro-
vide a potential benchmark for reimbursement, a pilot study was conducted to 
identify and valuate the resources related to conducting clinical cancer whole-
exome (cWES), transcriptome, and targeted panel sequencing in a cohort of 
pediatric cancer patients. MethOds: A cost model was calculated using 25 pedi-
atric cancer patients who underwent clinical genomic sequencing at Columbia 
University Medical Center. Our institutional workflow developed by the Precision 
in Pediatric Sequencing (PIPseq) Program in the Division of Pediatric Oncology and 
the Personalized Genomics Medicine Laboratory in the Department of Pathology 
guided the identification of resources and costs associated with NGS. Results: 
17 pediatric patients received cWES testing and 11 patients received transcrip-
tome testing using Illumina HiSeq 2500 technology. 7 patients received targeted 
cancer panel testing using Illumina MiSeq technology. The total cost per case per 
test [cWES (tumor/normal), $4,459; transcriptome (tumor), $1,764; targeted panel 
(tumor), $383) was calculated from summing the total variable cost (reagent cost, 
pathologist time) with the fixed cost per case (annual machine cost, annual main-
tenance, tech labor cost, informatics cost, space for NGS hardware, server time, 
NGS analysis lease, and data storage). Clinical utility was demonstrated by iden-
tifying a potentially actionable mutation in 24% of participants. cOnclusiOns: 
Since the reimbursement landscape for clinical genomic sequencing is currently 
unknown, a comprehensive cost calculation reflecting resource utilization across 
the whole sequencing workflow including costs associated with directed therapy 
based on molecular profiling results is necessary. These data serve as a starting 
point toward identifying and valuating resources associated with NGS and serve 
as a first step toward demystifying reimbursement for clinical genomic sequenc-
ing in Pediatric Oncology.
PCn176
aMnOg benefiT aSSeSSMenT fOr OnCOLOgiC and OrPhan drugS in 
gerMany – iMPLiCaTiOnS fOr PriCe diSCOunTS
Theidel U., Wahlers K., Mittendorf T.
Herescon GmbH, Hannover, Germany
Objectives: With the start of AMNOG in 2011, industry is demanded to submit 
and defend evidence as well as negotiate discounts for new drugs with an addi-
tional patient benefit in Germany. The National Association of Statutory Health 
Insurances (SpiBu) negotiates with a discount on the ex-factory price on top of 
a mandatory discount. Evaluating final prices, questions arise regarding factors 
might influence discounts and impact the German market especially for oncologic 
and orphan drugs. MethOds: A database containing detailed information for 
all past assessments was used to explore potential impact factors for discounts. 
Starting with an analysis of background information (discount, areas etc.) descrip-
tive statistics were employed. Furthermore, we analyzed past assessments with 
respect to: number and size of target population, results of the benefit assessment, 
change in ex-factory price, magnitude of discount, incorporation of quality of life 
evidence, and acceptance of comparator therapy among others. Results: Until 
June 2014 24 price negotiations were completed for oncologic and/or orphan drugs 
(neoplasm: 16, orphan drugs [w/o oncologics]: 8). It is inconclusive, if the scale of 
benefit influences the price discount. An additional benefit was granted by the 
G-BA in 21 of 24 cases. The magnitude of the discount tends to be higher in groups 
with smaller target populations and quality of life evidence has no influence on 
the negotiated discount. Discount rates might be smaller if the companies do 
not deviate from recommendations given by the G-BA. In addition to discounts, 
some companies needed to lower their ex-factory price. cOnclusiOns: Whereas 
binding and strict rules are in place for the benefit assessment itself, there is 
no algorithm for prediction of levels of price discounts. To decrease uncertainty 
for scenario planning a set algorithm or procedure would be preferable. Further 
research is needed to evaluate those criteria.
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algorithms mapping FACT-G to EuroQol (EQ-5D) [(Cheung, 2009), Ordinary Least 
Squares (OLS) and Tobit (Longworth, 2014)] and one from FACT-G to Time-Trade-
Off (Dobrez, 2007) were applied to data from the phase II study. The agreement 
between HSUVs was assessed using concordance correlation coefficients (CCCs), 
and paired t-tests for mean HSUVs. Results: HSUVs were generated for 93% of 
patients in the study. Mean predicted HSUVs using OLS and Tobit were statisti-
cally consistent (p-value= 0.947), whilst Cheung and Dobrez HSUVs were different 
from other algorithms (p-values < 0.05). The CCCs comparing OLS to Tobit and 
OLS to Cheung were 0.915 and 0.851, respectively. The CCCs comparing Dobrez 
to the EQ-5D algorithms were 0.629 (OLS), 0.619 (Tobit) and 0.783 (Cheung). The 
lowest and highest mean predicted HSUVs were estimated using OLS and Dobrez, 
respectively. cOnclusiOns: HSUVs can be estimated from FACT-O using FACT-G 
mapping algorithms. Comparable HSUVs were generated using OLS and Tobit algo-
rithms, whilst Cheung and Dobrez generated distinct HSUVs profiles. Without trial 
data directly comparing EQ-5D to FACT-O, it is difficult to identify the optimal 
mapping algorithm. Instead, a range of plausible mean HSUVs can be derived for 
use in cost-utility analyses.
PCn183
ObTaining indireCT uTiLiTieS wiTh The Sf-6d and The POrPuS-u in 
PrOSTaTe CanCer PaTienTS
Avila M.M.1, Pardo Y.1, Castells M.2, Ferrer F.3, Boladeras A.3, Pera J.3, Prada P.4, Guix B.5,  
de Paula B.6, Hernandez H.7, Pont A.1, Alonso J.1, Garin O.1, Ferrer M.1
1IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, 2Hospital Universitari de 
Bellvitge, L’Hospitalet de Llobregat, Spain, 3Institut Català d’Oncologia, L’Hospitalet de Llobregat, 
Spain, 4Hospital Universitario Central de Asturias, Oviedo, Spain, 5Fundación IMOR, Barcelona, 
Spain, 6Instituto Oncológico de Guipúzcoa, Gipuzkoa, Spain, 7Hospital Meixoeiro- Complejo 
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Objectives: To compare indirect utilities for prostate cancer patients obtained 
with a generic (SF-6D) and a disease-specific instrument (Patient Oriented Prostate 
Utility Scale, PORPUS-U). MethOds: This was a cross-sectional study of 480 pros-
tate cancer patients enrolled in two similar prospective cohorts. The first one 
included men diagnosed in 2003-2005 with localized prostate cancer (stage T1 
or T2) treated with radical prostatectomy, external radiotherapy, or interstitial 
radiotherapy at 10 hospitals. The second cohort included patients with stage T2 
or T3, treated with external radiotherapy alone or combined with brachytherapy, 
recruited in 2003–2006 at 6 hospitals. Annual computer-assisted telephone inter-
views carried out in both cohorts included several questionnaires: the SF-36v2 
(from which is derived the SF-6D), the PORPUS-U, and the Expanded Prostate 
Cancer Index Composite (EPIC), measuring urinary, bowel, sexual, and hormonal 
domains. ANOVA tests were performed to compare the means of utilities among 
severity groups of severity defined by EPIC items (severe, small or no relevant 
problem). Effect sizes between extreme groups were calculated to estimate the 
magnitude of differences. Results: Mean age was 66.8 years (SD= 6.4) at pros-
tate cancer diagnosis, 20.4% were treated with radical prostatectomy, 33.3% with 
brachytherapy, 26.7% with external radiotherapy, and 19.6% with combined radio-
therapy. The utilities indirectly obtained ranged 0.83-0.99 with PORPUS-U and 
0.61-0.84 with SF-6D. Both instruments showed significant differences according 
to problem severity of all domains measured with EPIC (p< 0.001). Utilities for 
patients without problems were higher than patients with severe problems. The 
effect sizes between the extreme groups with PORPUS-U and SF-6D were: 1.23 and 
1.24 for urinary; 1.03 and 0.75 for bowel; 0.98 and 0.96 for sexual; and 0.94 and 2.17 
for hormonal domains. cOnclusiOns: Our results suggest that both the generic 
index SF-6D and the disease-specific index PORPUS-U discriminated adequately 
the problems related to prostate cancer and their treatments.
PCn184
PaTienT SaTiSfaCTiOn regarding Their TreaTMenT and diSeaSe 
deCiSiOnS in infra-CenTiMeTriC breaST CanCer
Dalenc F.1, Pau D.2, Chauvet M.P.3, Belkacemi Y.4
1Institut Claudius Regaud, TOULOUSE, France, 2Roche, Boulogne Billancourt, France, 3CLCC Oscar 
Lambret, LILLE, France, 4Hôpital Henri Mondor, CRETEIL, France
Objectives: The primary objective of this French prospective multicenter non 
interventional ODISSEE study was to describe daily practice management of 
infra-centimetric Breast Cancer (BC). One secondary objective was to describe 
circumstances of diagnosis and disease announcement. Patients had to answer 
at inclusion a questionnaire regarding satisfaction of the management of their 
disease and upcoming treatment. MethOds: From May 2009 to March 2010, 616 
women with infiltrating, unifocal pT1ab, pN0 BC who underwent surgery were 
recruited by 116 centers. Follow-up period is 10 years. Clinical data, treatments 
and outcome were collected in routine visits. Regarding patient’s questionnaire 
at inclusion, seven topics (disease, treatment planned/organization/duration/
side effects, complementary exams needed and disease evolution) were to be 
discussed with their physician at disease discovery and patient’s satisfaction was 
evaluated. Results: 546 (89%) patients answered the questionnaire. All 7 topics 
were discussed with 52% of patients and none of them for 1% of patients. Disease 
and treatment planned was discussed for 98% of patients, for whom 67% were 
fully satisfied and 2% were not satisfied. While 60% of patients aged more than 
50 years old felt fully involved in their treatment choice, only 44% of patients 
aged less than 50 years old felt involved. Overall 12% of patients have considered 
that they have not been involved in their treatment choice. When time between 
disease discovery/physician visit/surgery is short (< 10 days), patient satisfac-
tion is high (> 85%) and when time is greater than 1 month, patient satisfaction 
falls below 40%. Physican specialty (surgeon/oncologist/gyneco-obstetrician) or 
location of disease management (public/private) does not show significant dif-
ference in patient’s satisfaction. cOnclusiOns: 57% of patients felt involved in 
the choice of their treatment, and 65% of patients were globally satisfied of their 
disease management. The shorter is the management of infra-centimetric breast 
cancer, the better is the satisfaction.
values ranged from 0.81–0.90. Pain, severity of disease, urinary and bowel function 
and performance status affected utility values in patients with PC. cOnclusiOns: 
For BC and PC, disease progression, exposure to CT and worsening performance 
status were associated with decreases in utility values. For corresponding disease 
stages, utility values tended to be lower for BC than PC, although heterogeneity of 
data across study populations makes comparisons challenging. No studies reported 
utility values according to response to treatment. Further research is warranted to 
improve the evidence available for CEA.
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heaLTh STaTe uTiLiTy vaLuaTiOn in radiO-iOdine refraCTOry 
differenTiaTed ThyrOid CanCer (rr-dTC)
Kerr C.1, Fordham B.1, de Freitas H.M.1, Pelletier C.L.2, Lloyd A.1
1ICON Plc, Oxford, UK, 2Eisai Inc, Woodcliff Lake, NJ, USA
Objectives: The study is designed to capture health related quality of life (HRQL) 
weights for radioiodine refractory differentiated thyroid cancer (RR-DTC) health 
states. Current treatment options for RR-DTC are limited, with generally poor prog-
nosis. As new treatments emerge for RR-DTC, associated cost-effectiveness evalu-
ations require appropriate preference-weighted HRQL values. MethOds: Vignette 
descriptions for RR-DTC treatment response and adverse event (AE) health states 
were informed by qualitative work conducted with RR-DTC patients in the US and 
interviews with 6 clinicians and nurses in the UK and US with RR-DTC treatment 
experience. Health states included: stable disease, treatment response, progressive 
disease, stable + grade III diarrhea, stable + grade III fatigue, stable + grade III hand 
foot syndrome (HFS), stable + grade I-II alopecia. The vignettes were reviewed by 
the UK and US clinical experts and piloted with UK general public participants 
in cognitive debrief interviews (n= 5). All vignettes were valued by a UK general 
public sample (n= 100) using a visual analogue scale (VAS) rating and time trade 
off (TTO) interview. Data were analysed using descriptive and regression meth-
ods. Results: The mean TTO health utilities for RR-DTC states ranged from treat-
ment response (0.86; 95% confidence intervals (CI) 0.83,0. 89); through stable disease 
(0.80; CI 0.77, 0.84); to progressive disease (0.50; CI 0.45, 0.56). AEs had a significant 
effect also (stable + grade I-II alopecia (0.75; CI 0.71, 0.79), + grade III fatigue (0.72; 
CI 0.67, 0.77), + grade III HFS (0.52; CI 0.46, 0.58), and + grade III diarrhea (0.42; CI 
0.36-0.48). cOnclusiOns: TTO utilities from this vignette study show clear dif-
ferentiation between RR-DTC states. The order and magnitude of HRQL impact 
demonstrated by the utility values reflected clinical opinion and elicited VAS scores. 
The values reported in this study are suitable for use in cost-effectiveness evalua-
tions for new treatments in RR-DTC.
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frenCh uTiLiTy eLiCiTaTiOn in PreviOuSLy TreaTed eurOPean PaTienTS 
wiTh indOLenT nOn-hOdgkin LyMPhOMa (inhL)
Bec M.1, Cognet M.1, Taieb V.1, Pacou M.2, Gauthier A.1
1Amaris, London, UK, 2Amaris, Paris, France
Objectives: Since October 2013, the Haute Autorité de Santé (HAS) requires cost-
effectiveness evidence to assess innovative health technologies. For cost-utility 
assessments, the HAS strongly recommends using French utility values. To date, 
the EQ-5D-3L and the HUI3 are the only instruments with a set of preferences 
values obtained from a representative sample of the French population. In order 
to inform a cost-utility model assessing pharmaceutical treatments of previously-
treated iNHL, this study aimed to review available utility values in France and 
to collect such estimates if necessary. MethOds: First, a reproducible MEDLINE 
search was undertaken to identify studies documenting utility values of previously 
treated iNHL and CLL in France. Then, a web-survey including socio-demographic 
and clinical questions as well as the EQ-5D-3L was conducted. Given the difficulty 
to recruit patients from the target population, the questionnaire was conducted 
in France, the United Kingdom, Germany, Italy and Spain. In line with the HAS 
guidelines, French tariffs from Chevalier et al. were applied to the collected EQ-5D 
data. Mean utility values were generated by health state: progression free and 
progressive disease. Results: Only one French cost-utility model conducted by 
Deconinck E. et al was identified as relevant, but the study used English utility 
inputs previously published by Wild et al. Results from the EQ-5D-3L questionnaire 
conducted, illustrated that quality of life was substantially higher in patients with 
stable disease versus patients with progression disease. Utilities were calculated 
with the following scoring function, U (E) = 1–u1-u2-u3-u4-u5–N3. Values between 
u1 to u5 depending of the 3 levels of the 5 dimensions: u1= 0; 0.15; 0.37, u2= 0; 0.21;. 
32; u3= 0; 0.16; 0.19; u4= 0; 0.11;. 026; u5= 0; 0.09; 0.20 and N3= 0.17. cOnclusiOns: 
EQ-5D is a standardised and validated generic instrument which can be used to 
elicit utility in iNHL patients. To our knowledge, these French utilities of previ-
ously-treated iNHL patients are the first to be published.
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generaTing heaLTh STaTe uTiLiTy vaLueS frOM faCT-Ovarian daTa 
COLLeCTed in a PhaSe ii MainTenanCe STudy in PLaTinuM SenSiTive 
reCurrenT Ovarian CanCer (STudy 19): a COMPariSOn Of MaPPing 
aLgOriThMS
Hettle R.1, Borrill J.2, Suri G.1, Wulff J.1
1PAREXEL Consulting, London, UK, 2AstraZeneca, Macclesfield, UK
Objectives: Where direct or indirect estimates of health state utility values 
(HSUVs) are not available, mapping algorithms can be used to generate HSUVs 
from health related quality of life data. In a phase II randomised study of olapa-
rib maintenance therapy in platinum-sensitive recurrent ovarian cancer, the 
Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire was 
used. Although no FACT-O mapping algorithms are currently available, several 
algorithms using FACT-General (G) domains of FACT-O have been published. In 
this analysis, we applied FACT-G mapping algorithms to the FACT-O data collected 
in the olaparib study and compared the HSUVs generated. MethOds: FACT-O 
data were collected at scheduled visits, and on treatment discontinuation. Three 
